Combined talimogene laherparepvec and binimetinib in patients with NRAS-mutated melanoma induces anti-tumor immunity
Yao, T.; Chen, R. E.; Yamada, M.; Moore, J. R.; Jimenez, M.; Huang, T.; Cornelius, L.; Ansstas, G.; Saligrama, N.; Chen, D. Y.
Show abstract
Abstract/SummaryImmune checkpoint blockade can produce long-lasting responses in patients with metastatic melanoma; notably, combined CTLA-4/PD-1 blockade has been associated with approximately 52% melanoma specific 10-year survival (1). Yet, nearly half of patients experience minimal clinical benefit, and intensified regimens come with substantial risk of severe immune-related toxicity. The precise determinants of immunotherapy response are incompletely defined, reflecting a complex interplay between tumor biology and host immunity. This is especially consequential for patients whose disease progresses on checkpoint blockade, for whom effective salvage options are limited. In a series of patients with NRAS-mutated melanoma refractory to checkpoint inhibitors, we found that intratumoral administration of talimogene laherparepvec (T-VEC) combined with MEK inhibitor binimetinib induced exceptional clinical responses by amplification of pre-existing T cell responses and induction of de novo tumor-reactive immunity.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.